Search for: "Summers v. Merck Sharp "
Results 1 - 7
of 7
Sorted by Relevance
|
Sort by Date
24 Feb 2014, 11:19 am
Merck KGaA v Merck Sharp & Dohme Corp & Others, a Chancery Division, England and Wales, ruling last week from Mr Justice Nugee [don't ask: the Kats haven't come across him either, but he is a Chancery judge], addressed an important preliminary issue. [read post]
17 May 2016, 10:11 am
This moggy will be speaking about enablement and sufficiency, in particular looking at the "plausibility" criterion that has become increasingly prominent in recent UK cases, for example Generics v Warner Lambert and Merck Sharp & Dohme v Ono Pharmaceutical. [read post]
28 Jun 2018, 1:42 pm
McCarthy & Holtus: Whether the Fair Debt Collection Practices Act applies to nonjudicial foreclosure proceedings; and Merck Sharp & Dohme v. [read post]
26 Aug 2019, 12:09 pm
: G 1/18, the decision | Coloplast v Salts: Should UK infringement proceedings be stayed if the patent has been opposed? [read post]
2 Nov 2020, 2:00 am
Merck Sharp & Dohme Limited (MSD) sought to invalidate Wyeth LLC’s (Wyeth) patent, EP (UK) 2 676 679 (the ‘Patent’), with Wyeth maintaining that the Patent was valid and counterclaiming for infringement on a quia timet basis in relation to MSD’s V114 product. [read post]
12 Sep 2008, 2:33 pm
: (IP finance), MARQUES international advertising portal goes live: (Class 46) Global - Patents Using patent landscaping analytics to improve the quality of M & A decisions: a review of Cox Enterprises’ $300M purchase of Adify: (IP Asset Maximiser Blog), Universities reap royalty rewards; investors ignore IP at their peril: (IAM), Top IP-owning nations claim faster patent processing; near harmonisation deal: (Intellectual Property Watch), Bosch, Xerox and Dupont sign up… [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO: (Managing… [read post]
